BioSpace News Archive

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a company developing treatments for severe neurodegenerative diseases, today published its financial results for the quarter ended June 30, 2023 and provided a business update.

The Danish biotech company, Tetra Pharm Technologies, announces completion of its new purpose-built headquarters facility to support long-term growth plans.

Elevation Oncology, Inc. (Nasdaq: ELEV) today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating EO-3021 in patients with advanced unresectable or metastatic solid tumors likely to express Claudin 18.2 including gastric, gastroesophageal junction, pancreatic or esophageal cancers.

Comera Life Sciences Holdings, Inc. today announced the peer-reviewed publication of preclinical data in the Journal of Pharmaceutical Sciences, which provide further evidence of caffeine’s viscosity reducing capabilities and support further development of caffeine as a viscosity reducing agent for subcutaneous (SQ) formulations of monoclonal antibodies.

Bionano Laboratories, a laboratory services business of Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that it has received Laboratory Accreditation from the College of American Pathologists (CAP) for its Clinical Laboratory Improvement Amendments (CLIA)-certified reference lab.

QSAM Biosciences Inc. today issued the following letter to its shareholders.

International medical imaging IT and cybersecurity company Sectra will provide Sectra One Cloud, its enterprise imaging cloud subscription service for diagnostic imaging, to a US based health system serving a multi-million strong patient community.

VintaBio named Jennifer Kingsley as its first Chief Commercial Officer to develop and implement the company’s commercial strategy.

HALO Precision Diagnostics (“HALO”), the leader in early disease detection using precision diagnostics, today announced the appointment of John Craighead, Ph.D., as chief operating officer and chief financial officer.

Seagen Phase 3 Trial of TUKYSA ® (tucatinib) in Combination with Antibody-Drug Conjugate ado-trastuzumab emtansine Meets Primary Endpoint of Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer.